Insights On Drug Development

  1. Selection And Evaluation Of Hybridization Capture Probes For LC/MS Analysis Of Oligonucleotides 4/23/2025

    To overcome challenges in oligonucleotide LC/MS bioanalysis, consider optimizing probe design by evaluating alternative chemistries like PNA for improved recovery and chromatographic performance.

  2. Advancing Cytokine, Immune Cell Characterization For Precision Bioanalysis 4/23/2025

    Unlock deeper insights into immune regulation and accelerate therapeutic discovery by adopting our next-generation inflammatory response assay.

  3. Expression Analysis Of CTLA-4, PD-1, And PD-L1 4/23/2025

    Advance personalized immunotherapy in NSCLC by leveraging qPCR-based analysis of CTLA-4, PD-1, and PD-L1 expression to identify predictive biomarkers and guide more effective treatment strategies.

  4. Multimodal Spatial Biomarker Analysis For Personalized Checkpoint Therapies 4/23/2025

    Enhance cancer treatment outcomes by prioritizing the identification and comprehensive analysis of predictive biomarkers like PD-L1, TIGIT, and tumor microenvironment cytokines.

  5. Optimizing qPCR For Broad-Range Transcript Detection In Anti-PD-1 Therapy 4/23/2025

    Optimize qPCR protocols for greater sensitivity and reproducibility to accurately measure immune-related gene expression and better identify patients who will benefit from anti-PD-1 immunotherapy.

  6. Quantifying, Mapping ATP Distribution Within Tissues To Inform Therapeutic Strategies 4/23/2025

    Leverage quantitative mass spectrometry imaging of ATP distribution to enhance tumor model selection and optimize targeted therapy development through precise mapping of metabolic activity.

  7. Accelerated Tox Offerings: A Recipe For Streamlining IND Applications 4/22/2025

    Accelerating the timeline to tox material can significantly enhance the drug development process, enabling faster IND submissions and providing crucial time savings for toxicology studies.

  8. Early-Phase Whole-Body PK 4/21/2025

    Accelerate your path to the clinic with Aliri’s cost-effective, label-free whole-body PK service — designed to deliver deeper insights, faster decisions, and better outcomes for your drug candidates.

  9. Label-Free Whole-Body Pharmacokinetics 4/21/2025

    This approach enables tissue-level analysis, delivering insights into efficacy at the site of action, uncovering potential safety concerns, and supporting smarter clinical candidate selection.

  10. Time: A Crucial Factor In Therapeutics Development 4/21/2025

    Accelerate your mRNA development and strengthen your response to emerging health threats with next-generation, cell-free DNA template solutions designed for speed, quality, and reliability.